Pfizer Inc. - Product Pipeline Review - 2016

Date: March 16, 2016
Pages: 419
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PF58724A452EN
Leaflet:

Download PDF Leaflet

Pfizer Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Pfizer Inc. - Product Pipeline Review - 2016’, provides an overview of the Pfizer Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Pfizer Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Pfizer Inc.
  • The report provides overview of Pfizer Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Pfizer Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Pfizer Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Pfizer Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pfizer Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pfizer Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Pfizer Inc. Snapshot
Pfizer Inc. Overview
Key Information
Key Facts
Pfizer Inc. - Research and Development Overview
Key Therapeutic Areas
Pfizer Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Pfizer Inc. - Pipeline Products Glance
Pfizer Inc. - Late Stage Pipeline Products
Pfizer Inc. - Clinical Stage Pipeline Products
Pfizer Inc. - Early Stage Pipeline Products
Pfizer Inc. - Drug Profiles
(naltrexone hydrochloride + oxycodone hydrochloride) ER
crizotinib
palbociclib
tofacitinib
epoetin zeta
gemtuzumab ozogamicin
tafamidis meglumine
(ertugliflozin + metformin hydrochloride)
(ertugliflozin + sitagliptin phosphate)
adalimumab biosimilar
axitinib
bevacizumab biosimilar
bococizumab
bosutinib
celecoxib
dacomitinib
ertugliflozin
gosogliptin
infliximab biosimilar
inotuzumab ozogamicin
meningococcal [serotype B] vaccine
pregabalin
pregabalin CR
rituximab biosimilar
rivipansel sodium
sildenafil citrate
sunitinib malate
tanezumab
trastuzumab biosimilar
ziprasidone mesylate
ascrinvacumab
Dekavil
domagrozumab
fosdagrocorat
gedatolisib
glasdegib
lorlatinib
Nimenrix
nirogacestat
PF-00489791
PF-00547659
PF-02545920
PF-04236921
PF-04457845
PF-05089771
PF-06290510
PF-06291874
PF-06425090
PF-06838435
ponezumab
temsirolimus
agatolimod sodium
pegfilgrastim
PF-06747775
filgrastim
HIV vaccine
PF-04136309
PF-04447943
PF-04518600
PF-04958242
PF-05082566
PF-05206388
PF-05230907
PF-05251749
PF-05402536
PF-06266047
PF-06273340
PF-06282999
PF-06293620
PF-06342674
PF-06412562
PF-06413367
PF-06427878
PF-06444752
PF-06444753
PF-06480605
PF-06647020
PF-06647263
PF-06648671
PF-06649751
PF-06650808
PF-06650833
PF-06651600
PF-06664178
PF-06669571
PF-06678552
PF-06700841
PF-06741086
PF-06751979
PF-06753512
PF-06755990
PF-06755992
PF-06801591
PF-06815345
Biologics for Undisclosed Indication
Biologics to Target PCSK-9 for Hypercholesterolemia
CE-355621
Drugs for Duchenne Muscular Dystrophy
GIBH-1008
GIBH-1010
GIBH-1018
GL-2045
HSD-621
J-17
Monoclonal Antibodies for Solid Tumor
MOR-8457
NIC7-DT
PD-0360324
PF-01247324
PF-06380101
PF-06447475
PF-06671008
PF-1355
PF-3845
PF-4989216
PF-5006739
PNU-120596
Proteins to Agonize MC4R for Obesity
RBT-301
Small Molecule 1 for Solid Tumors
Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor
Small Molecule to Inhibit IDO-1 for Oncology
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
Small Molecule to Inhibit TDO-2 for Oncology
Small Molecule to Modulate Androgen Receptor for Muscle Disorders
Small Molecules to Activate CFTR for Cystic Fibrosis
Small Molecules to Inhibit Mps1 for Breast Cancer
Small Molecules to Inhibit NMT for Malaria
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain
Vaccine 2 for Undisclosed Indication
Monoclonal Antibody Conjugates for Oncology
PF-00190434
PF-04445597
PF-46396
PPD-1
Small Molecule to Agonize LXR for Inflammation
Small Molecule to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation
Small Molecule to Antagonize Ghrelin Receptor for Alcoholism
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia
Small Molecule to Inhibit Acetyl-CoA Carboxylase for Metabolic Disorders
Small Molecule to Inhibit EZH2 for Oncology
Small Molecule to Inhibit MMP13 for Osteoarthritis
Small Molecule to Inhibit NS5A for HCV
Small Molecule to Inhibit PI3K Alpha and mTOR for Oncology
Small Molecule to Inhibit Pin1 for Oncology
Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome
Small Molecules for Inflammatory and Orphan Diseases
Small Molecules for Obesity and Diabetes
Small Molecules for Ulcerative Colitis and Crohn's Disease
Small Molecules to Agonize A1 Adenosine Receptor
Small Molecules to Agonize ADRB2 and Antagonize CHRM3 for COPD
Pfizer Inc. - Pipeline Analysis
Pfizer Inc. - Pipeline Products by Target
Pfizer Inc. - Pipeline Products by Route of Administration
Pfizer Inc. - Pipeline Products by Molecule Type
Pfizer Inc. - Pipeline Products by Mechanism of Action
Pfizer Inc. - Recent Pipeline Updates
Pfizer Inc. - Dormant Projects
Pfizer Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Pfizer Inc. - Company Statement
Pfizer Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Pfizer Inc., Key Information
Pfizer Inc., Key Facts
Pfizer Inc. - Pipeline by Indication, 2016
Pfizer Inc. - Pipeline by Stage of Development, 2016
Pfizer Inc. - Monotherapy Products in Pipeline, 2016
Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016
Pfizer Inc. - Partnered Products in Pipeline, 2016
Pfizer Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Pfizer Inc. - Out-Licensed Products in Pipeline, 2016
Pfizer Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Pfizer Inc. - Pre-Registration, 2016
Pfizer Inc. - Filing rejected/Withdrawn, 2016
Pfizer Inc. - Phase III, 2016
Pfizer Inc. - Phase II, 2016
Pfizer Inc. - Phase I, 2016
Pfizer Inc. - Preclinical, 2016
Pfizer Inc. - Discovery, 2016
Pfizer Inc. - Pipeline by Target, 2016
Pfizer Inc. - Pipeline by Route of Administration, 2016
Pfizer Inc. - Pipeline by Molecule Type, 2016
Pfizer Inc. - Pipeline Products by Mechanism of Action, 2016
Pfizer Inc. - Recent Pipeline Updates, 2016
Pfizer Inc. - Dormant Developmental Projects,2016
Pfizer Inc. - Discontinued Pipeline Products, 2016
Pfizer Inc., Other Locations
Pfizer Inc., Subsidiaries

LIST OF FIGURES

Pfizer Inc. - Pipeline by Top 10 Indication, 2016
Pfizer Inc. - Pipeline by Stage of Development, 2016
Pfizer Inc. - Monotherapy Products in Pipeline, 2016
Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016
Pfizer Inc. - Partnered Products in Pipeline, 2016
Pfizer Inc. - Out-Licensed Products in Pipeline, 2016
Pfizer Inc. - Pipeline by Top 10 Target, 2016
Pfizer Inc. - Pipeline by Route of Administration, 2016
Pfizer Inc. - Pipeline by Top 10 Molecule Type, 2016
Pfizer Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


AnaptysBio, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 24 pages
EGEN, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 24 pages
GenSpera, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 27 pages
ImmunoFrontier, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 22 pages
OncoImmune, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 24 pages

Ask Your Question

Pfizer Inc. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: